Join Inhalation Sciences’ CEO and Chairman for Outlook 2023 – post your questions now
(Stockholm, Sweden, 12 January 2023) Post your questions to ISAB CEO Manoush Masarrat and Chairman Daniel Spasic for their joint Redeye event on March 6th, 2023. The pair will take investor’s questions on 2022’s development and milestones, and how ISAB will keep growing momentum in 2023. Please submit your questions by February 27th, 2023.
At 10.00 CET Match 6th 2023, ISAB CEO Manoush Masarrat and Chairman Daniel Spasic will present Inhalation Sciences’ 2022 company update and outlook for 2023. They will provide strategic and operational perspectives on ISAB’s development and milestones in 2022 and present the company’s main priorities moving forward.
The company welcomes questions from its shareholders ahead of the presentation.
Questions should be submitted by February 27th, 2023, at the latest.
Please submit your questions to:
Gustaf Meyer: gustaf.meyer@redeye.se
or
Manoush Masarrat: manoush.masarrat@inhalation.se
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: